BACKGROUND
Patients with relapsed/refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. Herein, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase 3 trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Ch...
L. Xie, W. Yao, Y. Hua et al.· Annals of Oncology· 2 citations
Inspired by the bioelectric field-mediated ion regulation in native bone, a biomimetic carbon fiber reinforced polyetherketoneketone (CF/PEEK) scaffold incorporated with a bio-heterojunction was fabricated via 3D printing, liquid-phase chemistry and hydrothermal treatment, demonstrating that the CF/PEEK biomimetic scaf...
Yi-Tian Wang, Jia-Jun Liu, Tao-Jun Gong et al.· Biomaterials· 0 citations
Pulmonary metastasis in high‐grade conventional osteosarcoma remains a leading cause of treatment failure and mortality. Traditional monitoring methods are insufficient for early detection. This study aims to develop and validate an interpretable machine learning (ML) model using multi‐dimensional data from electronic...
Jian-Hua Mu, Yi-Tian Wang, Han Liu et al.· Cancer Medicine· 0 citations
The findings imply that within a high coagulation-related transcriptional score group, the interaction between iCAFs and APOE+ macrophages could facilitate OS progression, and the C3–C3AR1 signaling pathway might represent a promising target for future therapeutic strategies and coagulome monitoring in OS.
Jian-Hua Mu, Yi-Tian Wang, Han Liu et al.· Biomedicines· 0 citations
Percutaneous CPC injection was associated with pain relief, functional improvement, and radiographic stabilization in patients with UBCs, and suggest that CPC injection may represent a potential minimally invasive strategy for reconstruction of UBC-related bone defects.
Meng-Zhang Xie, Zheng-Xiao Lai, Yi Luo et al.· Frontiers in Surgery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.